These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 15322170)
1. Diabetes incidence is unaltered in glutamate decarboxylase 65-specific TCR retrogenic nonobese diabetic mice: generation by retroviral-mediated stem cell gene transfer. Arnold PY; Burton AR; Vignali DA J Immunol; 2004 Sep; 173(5):3103-11. PubMed ID: 15322170 [TBL] [Abstract][Full Text] [Related]
2. On the pathogenicity of autoantigen-specific T-cell receptors. Burton AR; Vincent E; Arnold PY; Lennon GP; Smeltzer M; Li CS; Haskins K; Hutton J; Tisch RM; Sercarz EE; Santamaria P; Workman CJ; Vignali DA Diabetes; 2008 May; 57(5):1321-30. PubMed ID: 18299317 [TBL] [Abstract][Full Text] [Related]
3. CD4(+) T cells from glutamic acid decarboxylase (GAD)65-specific T cell receptor transgenic mice are not diabetogenic and can delay diabetes transfer. Tarbell KV; Lee M; Ranheim E; Chao CC; Sanna M; Kim SK; Dickie P; Teyton L; Davis M; McDevitt H J Exp Med; 2002 Aug; 196(4):481-92. PubMed ID: 12186840 [TBL] [Abstract][Full Text] [Related]
4. Regulation of diabetes development by regulatory T cells in pancreatic islet antigen-specific TCR transgenic nonobese diabetic mice. Kanagawa O; Militech A; Vaupel BA J Immunol; 2002 Jun; 168(12):6159-64. PubMed ID: 12055228 [TBL] [Abstract][Full Text] [Related]
5. Identification of MHC class II-restricted peptide ligands, including a glutamic acid decarboxylase 65 sequence, that stimulate diabetogenic T cells from transgenic BDC2.5 nonobese diabetic mice. Judkowski V; Pinilla C; Schroder K; Tucker L; Sarvetnick N; Wilson DB J Immunol; 2001 Jan; 166(2):908-17. PubMed ID: 11145667 [TBL] [Abstract][Full Text] [Related]
6. Prevention of type I diabetes transfer by glutamic acid decarboxylase 65 peptide 206-220-specific T cells. Kim SK; Tarbell KV; Sanna M; Vadeboncoeur M; Warganich T; Lee M; Davis M; McDevitt HO Proc Natl Acad Sci U S A; 2004 Sep; 101(39):14204-9. PubMed ID: 15381770 [TBL] [Abstract][Full Text] [Related]
7. Selection of aberrant class II restricted CD8+ T cells in NOD mice expressing a glutamic acid decarboxylase (GAD)65-specific T cell receptor transgene. Ranheim EA; Tarbell KV; Krogsgaard M; Mallet-Designe V; Teyton L; McDevitt HO; Weissman IL Autoimmunity; 2004 Dec; 37(8):555-67. PubMed ID: 15763918 [TBL] [Abstract][Full Text] [Related]
8. Detection and characterization of T cells specific for BDC2.5 T cell-stimulating peptides. You S; Chen C; Lee WH; Wu CH; Judkowski V; Pinilla C; Wilson DB; Liu CP J Immunol; 2003 Apr; 170(8):4011-20. PubMed ID: 12682229 [TBL] [Abstract][Full Text] [Related]
9. A peptide of glutamic acid decarboxylase 65 can recruit and expand a diabetogenic T cell clone, BDC2.5, in the pancreas. Dai YD; Jensen KP; Lehuen A; Masteller EL; Bluestone JA; Wilson DB; Sercarz EE J Immunol; 2005 Sep; 175(6):3621-7. PubMed ID: 16148106 [TBL] [Abstract][Full Text] [Related]
10. IL-12 administration reveals diabetogenic T cells in genetically resistant I-Ealpha-transgenic nonobese diabetic mice: resistance to autoimmune diabetes is associated with binding of Ealpha-derived peptides to the I-A(g7) molecule. Trembleau S; Gregori S; Penna G; Gorny I; Adorini L J Immunol; 2001 Oct; 167(7):4104-14. PubMed ID: 11564833 [TBL] [Abstract][Full Text] [Related]
11. GAD-reactive CD4+ Th1 cells induce diabetes in NOD/SCID mice. Zekzer D; Wong FS; Ayalon O; Millet I; Altieri M; Shintani S; Solimena M; Sherwin RS J Clin Invest; 1998 Jan; 101(1):68-73. PubMed ID: 9421467 [TBL] [Abstract][Full Text] [Related]
12. Control of autoimmune diabetes in NOD mice by GAD expression or suppression in beta cells. Yoon JW; Yoon CS; Lim HW; Huang QQ; Kang Y; Pyun KH; Hirasawa K; Sherwin RS; Jun HS Science; 1999 May; 284(5417):1183-7. PubMed ID: 10325232 [TBL] [Abstract][Full Text] [Related]
13. Transgenic insulin (B:9-23) T-cell receptor mice develop autoimmune diabetes dependent upon RAG genotype, H-2g7 homozygosity, and insulin 2 gene knockout. Jasinski JM; Yu L; Nakayama M; Li MM; Lipes MA; Eisenbarth GS; Liu E Diabetes; 2006 Jul; 55(7):1978-84. PubMed ID: 16804066 [TBL] [Abstract][Full Text] [Related]
14. Retroviral delivery of GAD-IgG fusion construct induces tolerance and modulates diabetes: a role for CD4+ regulatory T cells and TGF-beta? Song L; Wang J; Wang R; Yu M; Sun Y; Han G; Li Y; Qian J; Scott DW; Kang Y; Soukhareva N; Shen B Gene Ther; 2004 Oct; 11(20):1487-96. PubMed ID: 15343360 [TBL] [Abstract][Full Text] [Related]
15. Antigen-specific immunomodulation for type 1 diabetes by novel recombinant antibodies directed against diabetes-associates auto-reactive T cell epitope. Dahan R; Gebe JA; Preisinger A; James EA; Tendler M; Nepom GT; Reiter Y J Autoimmun; 2013 Dec; 47():83-93. PubMed ID: 24090977 [TBL] [Abstract][Full Text] [Related]
16. Normal incidence of diabetes in NOD mice tolerant to glutamic acid decarboxylase. Jaeckel E; Klein L; Martin-Orozco N; von Boehmer H J Exp Med; 2003 Jun; 197(12):1635-44. PubMed ID: 12796471 [TBL] [Abstract][Full Text] [Related]
17. Prevention of autoimmune diabetes by immunogene therapy using recombinant vaccinia virus expressing glutamic acid decarboxylase. Jun HS; Chung YH; Han J; Kim A; Yoo SS; Sherwin RS; Yoon JW Diabetologia; 2002 May; 45(5):668-76. PubMed ID: 12107747 [TBL] [Abstract][Full Text] [Related]